<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01608984</url>
  </required_header>
  <id_info>
    <org_study_id>RIPCON-12</org_study_id>
    <nct_id>NCT01608984</nct_id>
  </id_info>
  <brief_title>Effects of Remote Ischemic PreConditioning in Off-pump Versus On-pump Coronary Artery Bypass Grafting(RIPCON)</brief_title>
  <acronym>RIPCON</acronym>
  <official_title>Effects of Remote Ischemic PreConditioning in Off-pump Versus On-pump Coronary</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose Remote ischemic preconditioning (RIPC) with transient upper limb ischemia reduces
      myocardial injury in patients undergoing On-pump coronary artery bypass (CABG) surgery with
      cross-clamp fibrillation or blood cardioplegia for myocardial protection. The molecular
      mechanisms leading to these effects are yet not fully understood. The purpose of the present
      study is to validate previous studies and gather further evidence for RIPC during CABG with
      blood cardioplegia, furthermore to determine, whether or not RIPC is still operative during
      Off-pump coronary artery bypass surgery (OPCAB), finally to elucidate intra-cellular
      mechanisms involved in myocardial protection by RIPC and their possible systemic mediators.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Remote ischemic preconditioning (RIPC) protocol before CABG (study arm A) or OPCAB (study arm
      B) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure
      cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary
      artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken
      before induction of cardioplegic cardiac arrest (A) or first coronary incision (B), and 5 to
      10 minutes after aortic unclamping during reperfusion of the myocardium (A) or 5 to 10
      minutes after the completion of the last anastomosis (B). Blood samples are taken prior to
      RIPC and during the first three postoperative days.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative extent of myocardial injury as measured by cardiac troponin T serum release over 72 hours after coronary bypass surgery and its area under the curve (AUC).</measure>
    <time_frame>72 hours postoperatively after CABG surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days and 1 year after coronary bypass surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events (MACCE)</measure>
    <time_frame>30 days and 1 year after coronary bypass surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days and 1 year after coronary bypass surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>30 days and 1 year after coronary bypass surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circulating microparticles after coronary bypass surgery</measure>
    <time_frame>perioperatively, 3 months and 1 year after coronary bypass surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myocardial Injury</condition>
  <arm_group>
    <arm_group_label>RIPC-CABG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery with blood cardioplegia for cardiac arrest (CABG) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 to 10 Minutes after aortic unclamping during reperfusion of the myocardium. Blood samples are taken up to 72 hours postoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control-CABG</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group: Coronary artery bypass grafting without RIPC protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIPC-OPCAB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remote ischemic preconditioning (RIPC) protocol before Off-pump coronary artery bypass surgery (OPCAB) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before first coronary artery incision and 5 to 10 Minutes after completion of the coronary anastomoses. Blood samples are taken up to 72 hours postoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control-OPCAB</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group: Off-pump Coronary artery bypass surgery without RIPC protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Remote ischemic preconditioning (RIPC)</intervention_name>
    <description>3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.
The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.</description>
    <arm_group_label>RIPC-CABG</arm_group_label>
    <arm_group_label>RIPC-OPCAB</arm_group_label>
    <other_name>RIPC: remote ischemic preconditioning</other_name>
    <other_name>CABG: coronary artery bypass grafting</other_name>
    <other_name>OPCAB: Off-pump coronary artery bypass surgery</other_name>
    <other_name>Isoflurane: 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane, Forane</other_name>
    <other_name>Sufentanil, Sufenta, (R-30730)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol</intervention_name>
    <description>The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.</description>
    <arm_group_label>Control-CABG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Off-pump Coronary artery bypass surgery without remote ischemic preconditioning</intervention_name>
    <description>The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.</description>
    <arm_group_label>Control-OPCAB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed triple vessel coronary artery disease

          -  Indication for surgical coronary revascularisation

          -  Written informed consent

          -  Age ≥ 18 years

        Exclusion Criteria:

          -  Age &gt; 80 years

          -  Instable angina/acute coronary syndrome

          -  Emergency surgery

          -  Recent myocardial infarction within 7 days prior to surgery

          -  Recent major infection/sepsis within 7 days prior to surgery

          -  Significant hepatic, renal oder pulmonary disease

          -  Other concomitant surgical procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Payam Akhyari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiovascular Surgery, University Hospital, Heinrich Heine University, Duesseldorf, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Albert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiovascular Surgery, University Hospital, Heinrich Heine University, Duesseldorf, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Artur Lichtenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiovascular Surgery, University Hospital, Heinrich Heine University, Duesseldorf, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerd Heusch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>nst. of Pathophysiology, University Duisburg-Essen, University Hospital Essen, Essen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Payam Akhyari, MD</last_name>
    <phone>+492118118331</phone>
    <email>payam.akhyari@med.uni-duesseldorf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Artur Lichtenberg, MD</last_name>
    <phone>+492118118331</phone>
    <email>artur.lichtenberg@med.uni-duesseldorf.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. Cardiovascular Surgery, University Hospital, Heinrich Heine University</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Payam Akhyari, MD</last_name>
      <phone>+492118118331</phone>
      <email>payam.akhyari@med.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Albert, MD</last_name>
      <phone>+492118118331</phone>
      <email>alexander.albert@med.uni-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Payam Akhyari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Albert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Hausenloy DJ, Erik Bøtker H, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, Lecour S, van Laake LW, Madonna R, Ruiz-Meana M, Schulz R, Sluijter JP, Yellon DM, Ovize M. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2013 Apr 1;98(1):7-27. doi: 10.1093/cvr/cvt004. Epub 2013 Jan 19. Review.</citation>
    <PMID>23334258</PMID>
  </reference>
  <reference>
    <citation>Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M. STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication. Circ Res. 2012 Jan 6;110(1):111-5. doi: 10.1161/CIRCRESAHA.111.259556. Epub 2011 Nov 23.</citation>
    <PMID>22116817</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2012</study_first_submitted>
  <study_first_submitted_qc>May 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <last_update_submitted>July 15, 2013</last_update_submitted>
  <last_update_submitted_qc>July 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>remote ischemic preconditioning</keyword>
  <keyword>coronary artery bypass grafting</keyword>
  <keyword>myocardial injury</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

